Stent restenosis, pathophysiology and treatment options: A 2010 update

Hellenic Journal of Cardiology

Volumn 52, Issue 2, 2011, Pages 149-157

  TsiGkas, GriGorios G ^a   Karantalis, Vasileios ^a   Hahalis, George ^a   Alexopoulos, Dimitrios ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Angioplasty; DES; Restenosis; Revascularization; Stents

Indexed keywords

ACETYLSALICYLIC ACID; ADENOVIRUS VECTOR; BIOLIMUS A9; CILOSTAZOL; CLOPIDOGREL; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; PACLITAXEL; PLACEBO; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ANTICOAGULANT THERAPY; BARE METAL STENT; BRACHYTHERAPY; CELL PROLIFERATION; CORONARY ARTERY BYPASS SURGERY; DEVICE THERAPY; DISEASE PREDISPOSITION; DRUG ELUTING STENT; DRUG MEGADOSE; GENE THERAPY; GENETIC SCREENING; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; INTRAVASCULAR ULTRASOUND; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LOADING DRUG DOSE; MOLECULAR BIOLOGY; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; REVIEW; RISK FACTOR; ROTATIONAL ATHERECTOMY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; VIRAL GENE DELIVERY SYSTEM;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY RESTENOSIS; GRAFT OCCLUSION, VASCULAR; HUMANS; STENTS;

EID: 79955143035     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Mack MJ, Brown PP, Kugelmass AD, et al. Current status and outcomes of coronary revascularization 1999 to 2002: 148,396 surgical and percutaneous procedures. Ann Thorac Surg. 2004; 77: 761-766.
2. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon an-gioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994; 331: 489-495.
3. Kasaoka S, Tobis JM, Akiyama T, et al. Angiographic and in-travascular ultrasound predictors of in-stent restenosis. J Am Coll Cardiol. 1998; 32: 1630-1635.
4. Kastrati A, Schömig A, Elezi S, Schühlen H, Wilhelm M, Dirschinger J. Interlesion dependence of the risk for resteno-sis in patients with coronary stent placement in in multiple lesions. Circulation. 1998; 97: 2396-2401.
5. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirsch-inger J, Schömig A. Vessel size and long-term outcome after coronary stent placement. Circulation. 1998; 98: 1875-1880.
6. Akiyama T, Moussa I, Reimers B, et al. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. J Am Coll Cardiol. 1998; 32: 1610-1618.
7. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994; 331: 496-501.
8. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349: 1315-1323.
9. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, pacli-taxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350: 221-231.
10. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005; 294: 1215-1223.
11. Tanabe K, Hoye A, Lemos PA, et al. Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. Am J Cardiol. 2004; 94: 115-118.
12. Lee MS, Pessegueiro A, Zimmer R, Jurewitz D, Tobis J. Clinical presentation of patients with in-stent restenosis in the drug-eluting stent era. J Invasive Cardiol. 2008; 20: 401-403.
13. Fujii K, Mintz GS, Kobayashi Y, et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation. 2004; 109: 1085-1088.
14. Iakovou I, Stankovic G, Montorfano M, et al. Is overdilata-tion of 3.0 mm sirolimus-eluting stent associated with a higher restenosis rate? Catheter Cardiovasc Interv. 2005; 64: 129-133.
15. Sianos G, Hofma S, Ligthart JMR, et al. Stent fracture and restenosis in the drug-eluting stent era. Catheter Cardiovasc Interv. 2004; 61: 111-116.
16. Tsigkas G, Davlouros P, Alexopoulos D. Angiographic and OCT imaging of a Nobori stent fracture. Eurointervention. 2009; 5(1) e.
17. Takebayashi H, Mintz GS, Carlier SG, et al. Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation. Circulation. 2004; 110: 3430-3434.
18. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Translu-minal Coronary Angioplasty Registry. Circulation. 1996; 94: 1818-1825.
19. Kastrati A, Schömig A, Seyfarth M, et al. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation. 1999; 99: 1005-1010.
20. Ribichini F, Steffenino G, Dellavalle A, et al. Plasma activity and insertion/deletion polymorphism of angiotensin I-con-verting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation. 1998; 97: 147-154.
21. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006; 47: 175-181.
22. Ahn CM, Park S, Hong JA, et al. Association of the polymorphism in the drug transporter gene ABCB1 with in-stent restenosis of Paclitaxel eluting stents in the Korean sbjects. J Am Coll Cardiol. 2006; 47(4 suppl B): 22B.
23. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999; 100: 1872-1878.
24. Corbett SJ, Cosgrave J, Melzi G, et al. Patterns of restenosis after drug-eluting stent implantation: Insights from a contemporary and comparative analysis of sirolimus- and pacli-taxel-eluting stents. Eur Heart J. 2006; 27: 2330-2337.
25. Rathore S, Kinoshita Y, Terashima M, et al. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug elut-ing stents. EuroIntervention. 10; 5: 841-846.
26. Bauters C, Banos JL, Van Belle E, Mc Fadden EP, Lablanche JM, Bertrand ME. Six-month angiographic outcome after successful repeat percutaneous intervention for in-stent restenosis. Circulation. 1998; 97: 318-321.
27. Reimers B, Moussa I, Akiyama T, et al. Long-term clinical follow-up after successful repeat percutaneous intervention for stent restenosis. J Am Coll Cardiol. 1997; 30: 186-192.
28. Yokoi H, Kimura T, Nakagawa Y, Nosaka H, Nobuyoshi M. Long-term clinical and quantitative angiographic follow-up after the Palmaz-Schatz stent restenosis. J Am Coll Cardiol. 1996; Supplement: 224-A.
29. Adamian M, Colombo A, Briguori C, et al. Cutting balloon angioplasty for the treatment of in-stent restenosis: a matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty. J Am Coll Cardi-ol. 2001; 38: 672-679.
30. Ajani AE, Waksman R, Sharma AK, et al. Three-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. Original WRIST. Washington Radiation for In-Stent Restenosis Trial. Cardiovasc Radiat Med. 2001; 2: 200-204.
31. Malhotra S, Teirstein PS. The SCRIPPS trial-catheter-based radiotherapy to inhibit coronary restenosis. J Invasive Cardi-ol. 2000; 12: 330-332.
32. Teirstein PS, Massullo V, Jani S, et al. Two-year follow-up after catheter-based radiotherapy to inhibit coronary restenosis. Circulation. 1999; 99: 243-247.
33. Alfonso F, Pérez-Vizcayno M-J, Hernandez R, et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardi-ol. 2006; 47: 2152-2160.
34. Saia F, Lemos PA, Hoye A, et al. Clinical outcomes for siro-limus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheter Cardiovasc Interv. 2004; 62: 283-288.
35. Radke PW, Kobella S, Kaiser A, et al. Treatment of in-stent restenosis using a paclitaxel-eluting stent: acute results and long-term follow-up of a matched-pair comparison with in-tracoronary beta-radiation therapy. Eur Heart J. 2004; 25: 920-925.
36. Torguson R, Sabate M, Deible R, et al. Intravascular brachy-therapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. Am J Cardiol. 2006; 98: 1340-1344.
37. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-elut-ing stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005; 293: 165-171.
38. Airoldi F, Rogacka R, Briguori C, et al. Comparison of clinical and angiographic outcome of sirolimus-eluting stent implantation versus cutting balloon angioplasty for coronary in-stent restenosis. Am J Cardiol. 2004; 94: 1297-1300.
39. Ellis SG, O'Shaughnessy CD, Martin SL, et al. Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. Eur Heart J. 2008; 29: 1625-1634.
40. Lemos PA, van Mieghem CAG, Arampatzis CA, et al. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes. Circulation. 2004; 109: 2500-2502.
41. Cosgrave J, Melzi G, Corbett S, et al. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. Am Heart J. 2007; 153: 354-359.
42. Mehilli J, Byrne RA, Tiroch K, et al. Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) Study. J Am Coll Cardiol. 2010; 55: 2710-2716.
43. Costa MA. Treatment of drug-eluting stent restenosis. Am Heart J. 2007; 153: 447-449.
44. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation. 2005; 111: 2257-2273.
45. Wilson GJ, Polovick JE, Huibregtse BA, Poff BC. Overlapping paclitaxel-eluting stents: long-term effects in a porcine coronary artery model. Cardiovasc Res. 2007; 76: 361-372.
46. Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation. 2009; 119: 680-686.
47. Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol. 2010; 55: 543-554.
48. Rasmussen K, Maeng M, Kaltoft A, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet. 2010; 375: 1090-1099.
49. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in reallife practice (COMPARE): a randomised trial. Lancet. 2010; 375: 201-209.
50. Wykrzykowska JJ, Räber L, de Vries T, et al. Biolimus-elut-ing biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy. EuroIntervention. 2009; 5: 310-317.
51. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009; 373: 897-910.
52. Katz MR, Van Praet F, de Canniere D, et al. Integrated coronary revascularization: percutaneous coronary intervention plus robotic totally endoscopic coronary artery bypass. Circulation. 2006; 114: I473-476.
53. Van Velzen JE, Schuijf JD, De Graaf FR, et al. Imaging of atherosclerosis: invasive and noninvasive techniques. Hellenic J Cardiol. 2009; 50: 245-263.
54. Hayase M, Oshima A, Zidar JP, et al. Comparison of ultrasound vs angiographic guidance for stenting in the CRUISE study. Circulation. 1997; 96(suppl 1): 1228.
55. Hoffmann R, Mintz GS, Mehran R, et al. Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents. J Am Coll Cardiol. 1998; 31: 43-49.
56. de Jaegere P, Mudra H, Figulla H, et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J. 1998; 19: 1214-1223.
57. Schiele F, Meneveau N, Vuillemenot A, et al. Impact of intra-vascular ultrasound guidance in stent deployment on 6-month restenosis rate: a multicenter, randomized study comparing two strategies--with and without intravascular ultrasound guidance. RESIST Study Group. REStenosis after Ivus guided STenting. J Am Coll Cardiol. 1998; 32: 320-328.
58. Sano K, Mintz GS, Carlier SG, et al. Treatment of restenotic drug-eluting stents: an intravascular ultrasound analysis. J Invasive Cardiol. 2007; 19: 464-468.
59. Kubo T, Maehara A, Mintz GS, et al. Analysis of the long-term effects of drug-eluting stents on coronary arterial wall morphology as assessed by virtual histology intravascular ultrasound. Am Heart J. 2010; 159: 271-277.
60. Prati F, Regar E, Mintz GS, et al. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J. 2010; 31: 401-415.
61. Lee S-W, Park S-W, Kim Y-H, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol. 2008; 51: 1181-1187.
62. Hausleiter J, Kastrati A, Mehilli J, et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation. 2004; 110: 790-795.
63. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006; 355: 2113-2124.
64. Axel DI, Kunert W, Göggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997; 96: 636-645.
65. Scheller B, Speck U, Romeike B, et al. Contrast media as carriers for local drug delivery. Successful inhibition of neointi-mal proliferation in the porcine coronary stent model. Eur Heart J. 2003; 24: 1462-1467.
66. Harrell RL, Rajanayagam S, Doanes AM, et al. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation. 1997; 96: 621-627.
67. Klugherz B, Jones P, Cui X, et al. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat Biotechnol. 2000; 18: 1181-1184.
68. Shi Y, Fard A, Galeo A, et al. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation. 1994; 90: 944-951.
69. Weintraub WS, Kosinski AS, Brown CL, 3rd, King SB, 3rd. Can restenosis after coronary angioplasty be predicted from clinical variables? J Am Coll Cardiol. 1993; 21: 6-14.
70. Kastrati A, Dirschinger J, Schömig A. Genetic risk factors and restenosis after percutaneous coronary interventions. Herz. 2000; 25: 34-46.
71. Van Tiel CM, Bonta PI, Rittersma SZH, et al. p27kip1-838C>A single nucleotide polymorphism is associated with restenosis risk after coronary stenting and modulates p27kip1 promoter activity. Circulation. 2009; 120: 669-676.
72. Kremastinos DT, Farmakis DT, Anastasiou-Nana M. Drug-eluting stents: where are we today? Hellenic J Cardiol. 2010; 51: 287-289.
73. Dixon SR, Grines CL, O'Neill WW. The year in intervention-al cardiology. J Am Coll Cardiol. 2009; 53: 2080-2097.